{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T06:10:58Z","timestamp":1696399858395},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T00:00:00Z","timestamp":1393286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>To retrospectively investigate and compare the effects of tumor necrosis factor alpha inhibitors (<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>i) on hepatic enzymes in ankylosing spondylitis (<jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content>) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis of the records of 94 <jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content> (66 male, 28 female) patients using <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>i was performed. Patients' clinical data, <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>ath <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>nkylosing <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>pondylitis <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>isease <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>ctivity (<jats:styled-content style=\"fixed-case\">BASDAI<\/jats:styled-content>) scores, erythrocyte sedimentation rate (<jats:styled-content style=\"fixed-case\">ESR<\/jats:styled-content>) and <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>\u2010reactive protein (<jats:styled-content style=\"fixed-case\">CRP<\/jats:styled-content>) levels were all examined. Liver function test (<jats:styled-content style=\"fixed-case\">LFT<\/jats:styled-content>s) results of patients before the treatment and 3, 6 and 12\u00a0months after treatment with <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>i were investigated. Aspartate transaminase (<jats:styled-content style=\"fixed-case\">AST<\/jats:styled-content>) and alanine transaminase (<jats:styled-content style=\"fixed-case\">ALT<\/jats:styled-content>) levels were investigated as indicators of <jats:styled-content style=\"fixed-case\">LFT<\/jats:styled-content>s.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The TNFi drugs used were infliximab (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>28), adalimumab (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>32) and etanercept (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>34). Pre\u2010treatment values of <jats:styled-content style=\"fixed-case\">ESR<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> CRP<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">BASDAI<\/jats:styled-content> scores were 28.3\u00a0\u00b1\u00a020.1\u00a0mm\/h, 1.5\u00a0\u00b1\u00a01.2\u00a0ng\/dL and 5.2\u00a0\u00b1\u00a00.8, respectively. Following <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>i use there was a statistically significant decrease in disease activity score (<jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.001). There was a significant increase in <jats:styled-content style=\"fixed-case\">LFT<\/jats:styled-content> at the third month evaluation compared to the initial values, while the average value was within normal range (baseline AST 19.6\u00a0\u00b1\u00a010.8\u00a0U\/L, <jats:styled-content style=\"fixed-case\">ALT<\/jats:styled-content> 19.1\u00a0\u00b1\u00a06.4\u00a0U\/L, third month <jats:styled-content style=\"fixed-case\">AST<\/jats:styled-content> 31.3\u00a0\u00b1\u00a021.6\u00a0U\/L, <jats:styled-content style=\"fixed-case\">ALT<\/jats:styled-content> 28.1\u00a0\u00b1\u00a018.1\u00a0U\/L, <jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.001). Drug group comparison analysis revealed a significant difference in the adalimumab group value at the end of the first year, but no other significant difference in the data for the other months (<jats:italic>P\u00a0<\/jats:italic>&gt;<jats:italic>\u00a0<\/jats:italic>0.05). No significant correlation was determined between initial disease activity scores and <jats:styled-content style=\"fixed-case\">LFT<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>TNFi use\u2010associated rises in hepatic enzymes were determined compared to pre\u2010treatment but the mean values remained within normal limits. Considering the cases in the literature, in daily practice patients must be carefully monitored for liver function before treatment and at follow\u2010up.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.12311","type":"journal-article","created":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T10:02:43Z","timestamp":1393322563000},"page":"548-552","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of ankylosing spondylitis with <scp>TNF<\/scp> inhibitors does not have adverse effect on results of liver function tests: a longitudinal study"],"prefix":"10.1111","volume":"18","author":[{"given":"Erhan","family":"Capkin","sequence":"first","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation Division Rheumatology Farabi Hospital Karadeniz Technical University Medical School Trabzon Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Karkucak","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation Division Rheumatology Farabi Hospital Karadeniz Technical University Medical School Trabzon Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arif M.","family":"Cosar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Division of Gastroenterology Karadeniz Technical University Medical School Trabzon Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emel","family":"Ak","sequence":"additional","affiliation":[{"name":"Igd\u0131r state Hospital Igd\u0131r Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adem","family":"Karaca","sequence":"additional","affiliation":[{"name":"Mus State Hospital Mus Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferhat","family":"Gokmen","sequence":"additional","affiliation":[{"name":"Canakkale Onsekiz mart University Medical School \u00c7anakkale Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bayram S.","family":"Budak","sequence":"additional","affiliation":[{"name":"Antalya State Hospital Antalya Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Tosun","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation Division Rheumatology Farabi Hospital Karadeniz Technical University Medical School Trabzon Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,2,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(02)00052-1"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2008.07.005"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gcb.2008.04.010"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.114363"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gcb.2007.11.002"},{"key":"e_1_2_7_7_1","first-page":"164","article-title":"Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis","volume":"27","author":"Braun J","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-005-0169-y"},{"key":"e_1_2_7_9_1","unstructured":"AbramsonS(2003)A safety update on the TNF alpha blocking agents. FDA Briefing document. Arthritis Advisory committee. March 3."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.112136"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05246-0"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032821"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200626110-00008"},{"key":"e_1_2_7_14_1","first-page":"1098","article-title":"The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis","volume":"31","author":"Hansen KE","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2007.12.009"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2009.07.003"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0b013e3283383c7c"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.127233"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.10.003"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e318228bcb6"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.4065\/76.1.84"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2003.09.003"},{"key":"e_1_2_7_23_1","first-page":"25","article-title":"Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab","volume":"24","author":"Cravo M","year":"2010","journal-title":"Bio Drugs"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/039463200902200234"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1179-y"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0253-y"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.433"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12311","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.12311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T23:12:02Z","timestamp":1696374722000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.12311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,25]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1111\/1756-185X.12311"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.12311","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,25]]},"assertion":[{"value":"2014-02-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}